Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

Cidara Therapeutics, Inc. announced the initiation of its Phase IIa trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus.